Smoking Cessation as the Primary Strategy to Reduce Amputation Risk in Patients with Diabetic Foot Ulcers

1. Glycemic Control – Do Not Intensify When Target Is Already Met

For most adults with type 2 diabetes, the recommended A1c target is < 7 % (guideline recommendation)【1】【2】.
Adding additional glucose‑lowering agents (e.g., canagliflozin) while A1c is already at goal increases hypoglycemia risk without addressing the main driver of amputation risk【3】.
The ACCORD trial showed that intensive glycemic control (mean A1c ≈ 6.4 %) versus standard control (mean A1c ≈ 7.5 %) raised mortality and did not clearly reduce macrovascular complications【3】 (Level A evidence).
Intensifying insulin therapy in a patient with A1c ≈ 6.9 % raises hypoglycemia risk and offers no benefit【3】 (Level A).

All individuals with diabetes and foot ulcers should receive aggressive cardiovascular risk management, with smoking cessation as a core component (International Working Group on the Diabetic Foot)【4】【5】.
Observational data demonstrate that continued smoking markedly increases death, myocardial infarction, and amputation rates compared with smoking cessation in patients with peripheral artery disease【1】 (moderate‑quality evidence).
Clinicians must advise cessation at every visit and document the recommendation【1】.
Comprehensive cessation programs (behavioral therapy, nicotine‑replacement therapy achieving ~16 % one‑year abstinence, or bupropion achieving ~30 % one‑year abstinence) are effective and should be offered【1】 (Level B).
Regular follow‑up enhances cessation success (≈ 5 % with physician‑led follow‑up vs 0.1 % without)【1】 (Level B).

Prescribe a statin for lipid control in all diabetic foot‑ulcer patients (IWGDF recommendation)【4】【5】.
Initiate low‑dose aspirin or clopidogrel for antiplatelet therapy (IWGDF recommendation)【4】【5】.
Treat hypertension aggressively according to standard cardiovascular guidelines (IWGDF recommendation)【4】【5】.

A history of two foot ulcers within the past 12 months places a patient in International Working Group on the Diabetic Foot (IWGDF) Risk Category 3 – the highest risk tier【6】【7】.
Patients in Risk Category 3 require multidisciplinary foot‑care follow‑up every 1–3 months【6】【7】 (guideline).
Approximately 50 % of diabetic foot‑ulcer patients have co‑existing peripheral artery disease, a condition accelerated by smoking【4】【5】【6】 (observational).

Screen for peripheral artery disease (PAD) using history of claudication and pedal‑pulse examination【2】.
Perform an ankle‑brachial index (ABI) in all at‑risk patients because many PAD cases are asymptomatic【2】【8】 (guideline).
If PAD is confirmed or strongly suspected, refer for vascular assessment and consider revascularization when indicated【4】【5】.

Refer patients to a coordinated diabetic foot‑care team (podiatry, vascular surgery, infectious disease, endocrinology) for comprehensive management【8】 (guideline).

Instruct patients to inspect feet daily (using a mirror if needed), avoid walking barefoot or in thin‑soled footwear, wash feet with lukewarm water, dry between toes, and apply emollient to dry skin【7】.
Advise immediate reporting of any temperature rise, blisters, cuts, or color changes【7】.
Home foot‑temperature monitoring: a temperature difference > 2.2 °C persisting for two consecutive days should trigger activity reduction and prompt provider contact【7】.

Provide therapeutic shoes that achieve ≥ 30 % plantar pressure reduction for patients with prior plantar ulcers【7】 (evidence‑based recommendation).
Ensure consistent wear of prescribed footwear both indoors and outdoors【7】.
Schedule professional callus removal every 1–3 months to prevent pressure‑related ulcer recurrence【7】.

Do not intensify glucose‑lowering therapy when A1c is already at target; this raises hypoglycemia risk without benefit【3】.
Do not rely solely on glycemic optimization to prevent amputation; smoking cessation and comprehensive cardiovascular risk management are equally or more critical【4】【1】【5】.
Do not use palpable pedal pulses alone to rule out PAD; obtain an ABI if PAD is suspected【2】【8】.
Do not permit patients to self‑debride calluses with over‑the‑counter products, as this can cause chemical burns and ulceration【6】.
Do not underestimate the role of properly fitted therapeutic footwear; shoes with proven pressure‑relief are essential for preventing recurrent ulcers【7】.